Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdiaVita and Glutathione in Autism Spectrum Disorder
NCT07304440Phase 1Recruiting
- Sponsor
- Adia Med, LLC
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of AdiaVita in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Adia Med, LLC. Primary endpoint: Autism Treatment Evaluation Checklist at 6 months. Started May 2026; status: recruiting.
02
Drugs
AdiaVita
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07304440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304440.